Skip to content

Nuclear Medicine

Select

FLEXdose SELECT Delivery Program

The FLEXdose SELECT Delivery Program; offering up to 5 delivery options every day of the week, aims to enhance the precision, effectiveness, and convenience of SIR-Spheres Y-90 resin microsphere therapy.

The SIR-Spheres FLEXdose SELECT Delivery Program offers significant value to both patients and physicians in the treatment of metastatic colorectal cancer (mCRC) using Y-90 microspheres.

The Treating Physician:

  • Ease of Use
    Streamlined ordering and delivery process for seamless integration into your clinical workflow.
  • Convenience
    On-demand access to personalized Y-90 resin doses tailored to your patient's needs.
    Flexible scheduling options to accommodate your treatment timelines.
  • Flexibility
    Customizable dose ranges to precisely match your prescribed treatment plan.
    Adaptable to various delivery techniques preferred by your clinical team.
  • Control
    Empowers your treatment team with full control of dosing and administration.
  • Adaptability
    It accommodates various delivery techniques preferred by different clinical teams.

For Patients:

  • Customized Treatment
    Patients receive a treatment plan precisely tailored to their specific tumor burden and characteristics.
  • Precise Activity Delivered
    Optimal personalized dosing delivers the exact required radioactive activity.
  • Optimal Tumor Coverage
    Careful selection of microsphere volume ensures comprehensive tumor coverage and maximized absorbed dose.
  • Enhanced Safety for Healthy Liver
    Minimized exposure of healthy liver tissue to radiation, reducing potential side effects and complications.

The Activity* You Want. The Flexibility You Need.

*SIR-Spheres Y-90 resin microspheres (SIR-Y002) calibrate at 6pm EST to 1.8 GBq +/- 10%.



Order SIR-Spheres Y-90 resin microspheres

Should you have any questions, please contact your representative for assistance.

Resources

Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.